| HOME >> MEDICINE >> TECHNOLOGY |
Renminbi (RMB) appreciation and its impact on the pharmaceutical industry 63
3. China - Healthcare system and drug regulatory analysis 66
China - Key findings 66
Healthcare expenditure 66
Healthcare system 66
Healthcare insurance 66
Regulatory issues 67
Pricing and reimbursement issues 67
China - Healthcare expenditure 69
China - Healthcare system 71
Regulatory healthcare bodies 71
Ministry of Health sets the high-level policies 72
Ministry of Human Resources and Social Security oversees the national medical insurance system 72
The National Council for Social Security Fund is often surrounded by scandals 72
China Insurance Regulatory Commission regulates private insurance sector 72
National Development and Reform Commission oversees overall policy development 72
State Administration for Industry and Commerce 73
China's healthcare reform 73
China healthcare reform, 2010-2020 "The Glorious Ten"? 75
China - Health insurance 77
China - Social health insurance 78
The Introduction of the urban employee Basic Medical Insurance System has improved health insurance coverage in cities 79
The unemployed are offered a very basic health insurance 80
Rural health insurance coverage is increasing but the benefits are insufficient 80
China - Private health insurance 82
Primary versus secondary care 83
China - Regulatory issues 84
State Food and Drug Administration is the watchdog for drug registration and safety issues 84
Evolution of the SFDA 85
Drug classification in China 87
Drug Monitoring Period 87
Drug registration in China 87
New Provisions for Drug Registration led to a fall in drug approvals 91
New pathway for expedited drug approval 91
GMP regulation in China 92
Intellectual proper
'/>"/>
| SOURCE Reportlinker Copyright©2010 PR Newswire. All rights reserved |